

## **GOLDEN AGRI-RESOURCES LTD**

## Half Year Financial Statement And Dividend Announcement

## **FINANCIAL HIGHLIGHTS**

|  | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> | Change<br><u>%</u> |
|--|-------------------------------------|-------------------------------------|--------------------|
| Revenue  | 6,151,922                           | 5,141,882                           | 19.6               |
| Gross Profit                                     | 868,506                             | 671,537                             | 29.3               |
| EBITDA <sup>1</sup>                              | 566,250                             | 494,606                             | 14.5               |
| Underlying profit <sup>2</sup>                   | 232,466                             | 188,711                             | 23.2               |
| Net profit attributable to owners of the Company | 160,259                             | 102,431                             | 56.5               |

#### Notes:

- (1) Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net (loss)/gain from changes in fair value of biological assets and foreign exchange loss.
- (2) Net profit attributable to owners of the Company excluding net effect of net gain or loss from changes in fair value of biological assets and depreciation of bearer plants and other non-operating items (foreign exchange gain or loss, net tax impact from tax-based asset revaluations, and other deferred tax income or expense).

## A Condensed interim consolidated income statement and consolidated statement of comprehensive income

## UNAUDITED CONSOLIDATED INCOME STATEMENT FOR THE PERIOD ENDED 30 JUNE 2025

|  | <u>Note</u> | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> | Change<br><u>%</u> |
|--|-------------|-------------------------------------|-------------------------------------|--------------------|
| Revenue  | E4          | 6,151,922                           | 5,141,882                           | 19.6               |
| Cost of sales (Note 1)                               |             | (5,283,416)                         | (4,470,345)                         | 18.2               |
| Gross Profit   | _           | 868,506                             | 671,537                             | 29.3               |
| Operating expenses                                   |             |                                     |                                     |                    |
| Selling expenses (Note 1)                            |             | (344,231)                           | (253,268)                           | 35.9               |
| General and administrative expenses                  |             | (190,981)                           | (184,105)                           | 3.7                |
| Total operating expenses                             |             | (535,212)                           | (437,373)                           | 22.4               |
| Operating profit                                     |             | 333,294                             | 234,164                             | 42.3               |
| Other income/(expenses)                              |             |                                     |                                     |                    |
| Financial income                                     |             | 31,013                              | 36,148                              | (14.2)             |
| Financial expenses                                   |             | (113,095)                           | (122,102)                           | (7.4)              |
| Share of results of associated companies, net of tax |             | 2,258                               | 3,710                               | (39.1)             |
| Share of results of joint ventures, net of tax       |             | 13,640                              | 6,940                               | 96.5               |
| Foreign exchange loss                                |             | (23,919)                            | (48,274)                            | (50.5)             |
| Other income   |             | 7,746                               | 46,029                              | (83.2)             |
|  | _           | (82,357)                            | (77,549)                            | 6.2                |
| Profit before tax                                    | E5          | 250,937                             | 156,615                             | 60.2               |
| Income tax   | E6          | (77,350)                            | (35,381)                            | 118.6              |
| Profit for the period                                | _           | 173,587                             | 121,234                             | 43.2               |
| Attributable to:                                     |             |                                     |                                     |                    |
| Owners of the Company                                |             | 160,259                             | 102,431                             | 56.5               |
| Non-controlling interests                            |             | 13,328                              | 18,803                              | (29.1)             |
| -  | _           | 173,587                             | 121,234                             | 43.2               |

#### Note:

## (1) Reclassifications and Comparatives

Certain financial information relating to freight cost and other related expenses have been reclassified to cost of sales during the current financial period. Accordingly, the comparative figures have been reclassified and restated to conform with the presentation in the consolidated income statement for the period ended 30 June 2025. The effects of the reclassification were as follows:

|                  | As previously<br>reported in<br>1st Half 2024<br><u>US\$'000</u> | reported in 1st Half 2024 Reclassification |             |  |
|------------------|--|--|-------------|--|
| Cost of sales    | (4,221,895)  | (248,450)                                  | (4,470,345) |  |
| Selling expenses | (501,718)  | 248,450                                    | (253,268)   |  |

# A Condensed interim consolidated income statement and consolidated statement of comprehensive income (cont'd)

## UNAUDITED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE PERIOD ENDED 30 JUNE 2025

|   | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> |
|---|-------------------------------------|-------------------------------------|
| Profit for the period   | 173,587                             | 121,234                             |
| Other comprehensive income/(loss):                                    |                                     |                                     |
| Items that will not be reclassified subsequently to profit or loss:   |                                     |                                     |
| Actuarial loss on post-employment benefits                            | (3,721)                             | (249)                               |
| Share of other comprehensive (loss)/income of joint ventures          | (63)                                | 41                                  |
| Changes in fair value of financial assets at fair value through other |                                     |                                     |
| comprehensive income  | 21,896                              | (12,115)                            |
| Items that may be reclassified subsequently to profit or loss:        |                                     |                                     |
| Foreign currency translation differences on consolidation             | 13,888                              | (12,828)                            |
| Share of other comprehensive income/(loss) of:                        |                                     |                                     |
| Joint ventures  | 679                                 | (3,570)                             |
| Associated companies  | (115)                               | (1,468)                             |
| Other comprehensive income/(loss), net of tax                         | 32,564                              | (30,189)                            |
| Total comprehensive income for the period, net of tax                 | 206,151                             | 91,045                              |
| Total comprehensive income attributable to:                           |                                     |                                     |
| Owners of the Company   | 192,803                             | 73,026                              |
| Non-controlling interests   | 13,348                              | 18,019                              |
| -   | 206,151                             | 91,045                              |
|   |                                     |                                     |

## **ADDITIONAL INFORMATION**

Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net (loss)/gain from changes in fair value of biological assets and foreign exchange loss ("EBITDA")

|   | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> | Change<br><u>%</u> |
|---|-------------------------------------|-------------------------------------|--------------------|
| Earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net (loss)/gain from changes in fair value of biological assets and foreign exchange loss ("EBITDA") | 566,250                             | 494,606                             | 14.5               |
| Interest on borrowings  | (109,829)                           | (120,800)                           | (9.1)              |
| Depreciation and amortisation   | (180,813)                           | (177,841)                           | 1.7                |
| Net (loss)/gain from changes in fair value of biological assets   | (752)                               | 8,924                               | n.m.               |
| Foreign exchange loss   | (23,919)                            | (48,274)                            | (50.5)             |
| Profit before tax   | 250,937                             | 156,615                             | 60.2               |

Note: n.m. - not meaningful.

## B Condensed interim statements of financial position

## UNAUDITED STATEMENTS OF FINANCIAL POSITION

|                                  |             | Gro                                   | oup                                    | Com                                   | pany                                   |
|----------------------------------|-------------|---------------------------------------|--|---------------------------------------|--|
|                                  | <u>Note</u> | As at<br>30/6/2025<br><u>US\$'000</u> | As at<br>31/12/2024<br><u>US\$'000</u> | As at<br>30/6/2025<br><u>US\$'000</u> | As at<br>31/12/2024<br><u>US\$'000</u> |
| Assets                           |             |                                       |  |                                       |  |
| Current Assets                   |             |                                       |  |                                       |  |
| Cash and cash equivalents        | E9          | 470,961                               | 435,924                                | 301                                   | 497                                    |
| Short-term investments           | E10         | 574,580                               | 563,903                                | -                                     | -                                      |
| Trade receivables                |             | 981,644                               | 885,546                                | -                                     | -                                      |
| Other current assets             | E11         | 576,049                               | 729,894                                | 6,021                                 | 6,016                                  |
| Biological assets                |             | 85,122                                | 85,874                                 | -                                     | -                                      |
| Inventories                      | _           | 1,964,878                             | 1,950,294                              |                                       |  |
|                                  | _           | 4,653,234                             | 4,651,435                              | 6,322                                 | 6,513                                  |
| Non-Current Assets               |             |                                       |  |                                       |  |
| Long-term receivables and assets | E12         | 65,575                                | 49,100                                 | -                                     | -                                      |
| Long-term investments            | E13         | 1,449,048                             | 1,484,992                              | 224,457                               | 229,457                                |
| Subsidiary companies             |             | -                                     | -                                      | 3,153,293                             | 3,153,293                              |
| Associated companies             |             | 28,066                                | 27,612                                 | -                                     | -                                      |
| Joint ventures                   |             | 260,655                               | 246,442                                | -                                     | -                                      |
| Investment properties            |             | 75                                    | 76                                     | -                                     | -                                      |
| Property, plant and equipment    |             | 2,597,673                             | 2,549,134                              | -                                     | -                                      |
| Bearer plants                    |             | 1,259,970                             | 1,284,615                              | -                                     | -                                      |
| Tax recoverable                  |             | 118,922                               | 174,032                                | -                                     | -                                      |
| Deferred tax assets              |             | 82,315                                | 82,835                                 | -                                     | -                                      |
| Intangible assets                |             | 150,264                               | 143,095                                |                                       |  |
|                                  | _           | 6,012,563                             | 6,041,933                              | 3,377,750                             | 3,382,750                              |
| Total Assets                     | _           | 10,665,797                            | 10,693,368                             | 3,384,072                             | 3,389,263                              |

## B Condensed interim statements of financial position (cont'd)

## UNAUDITED STATEMENTS OF FINANCIAL POSITION (cont'd)

|                                      |             | Group                                 |  | Com                                   | pany                                   |  |
|--------------------------------------|-------------|---------------------------------------|--|---------------------------------------|--|--|
|                                      | <u>Note</u> | As at<br>30/6/2025<br><u>US\$'000</u> | As at<br>31/12/2024<br><u>US\$'000</u> | As at<br>30/6/2025<br><u>US\$'000</u> | As at<br>31/12/2024<br><u>US\$'000</u> |  |
| Liabilities and Equity               |             |                                       |  |                                       |  |  |
| Current Liabilities                  |             |                                       |  |                                       |  |  |
| Short-term borrowings                | E15         | 1,768,841                             | 1,838,436                              | -                                     | -                                      |  |
| Bonds and notes payable              | E15         | 98,883                                | 116,084                                | -                                     | -                                      |  |
| Lease liabilities                    | E15         | 15,468                                | 16,736                                 | -                                     | -                                      |  |
| Trade and trust receipts payables    |             | 717,950                               | 606,560                                | -                                     | -                                      |  |
| Other payables                       | E14         | 663,559                               | 573,107                                | 5,421                                 | 5,035                                  |  |
| Taxes payable                        | _           | 52,191                                | 57,225                                 |                                       |  |  |
|                                      | -           | 3,316,892                             | 3,208,148                              | 5,421                                 | 5,035                                  |  |
| Non-Current Liabilities              |             |                                       |  |                                       |  |  |
| Long-term borrowings                 | E15         | 1,254,830                             | 1,470,649                              | -                                     | -                                      |  |
| Bonds and notes payables             | E15         | 181,435                               | 213,935                                | -                                     | -                                      |  |
| Lease liabilities                    | E15         | 45,691                                | 49,679                                 | -                                     | -                                      |  |
| Deferred tax liabilities             |             | 151,920                               | 157,357                                | -                                     | -                                      |  |
| Long-term payables and liabilities   | E16         | 206,956                               | 215,367                                | 91,826                                | 18,341                                 |  |
|                                      | -           | 1,840,832                             | 2,106,987                              | 91,826                                | 18,341                                 |  |
| Total Liabilities                    | -           | 5,157,724                             | 5,315,135                              | 97,247                                | 23,376                                 |  |
| Equity Attributable to Owners of the | Compan      | y                                     |  |                                       |  |  |
| Issued capital                       | E17         | 320,939                               | 320,939                                | 320,939                               | 320,939                                |  |
| Share premium                        |             | 1,216,095                             | 1,216,095                              | 1,850,965                             | 1,850,965                              |  |
| Treasury shares                      | E17         | (39,825)                              | (39,825)                               | (39,825)                              | (39,825)                               |  |
| Other paid-in capital                |             | 184,318                               | 184,318                                | -                                     | -                                      |  |
| Other reserves                       | Ī           | 24.474                                | 04.474                                 | 04.474                                | 04.474                                 |  |
| Option reserve                       |             | 31,471                                | 31,471                                 | 31,471                                | 31,471                                 |  |
| Currency translation reserve         |             | (72,594)                              | (86,887)                               | (400,020)                             | (400,030)                              |  |
| Fair value reserve                   |             | (397,678)                             | (419,574)                              | (408,938)                             | (408,938)                              |  |
| PRC statutory reserve                |             | 6,594                                 | 6,594                                  | -                                     | -                                      |  |
| Others                               | Ĺ           | 42,912                                | 46,557                                 | (077,407)                             | (077.407)                              |  |
| Battanlandan                         |             | (389,295)                             | (421,839)                              | (377,467)                             | (377,467)                              |  |
| Retained earnings                    | -           | 3,924,426                             | 3,842,504                              | 1,532,213                             | 1,611,275                              |  |
| Non-Controlling Interests            |             | 5,216,658<br>201,415                  | 5,102,192<br>276,041                   | 3,286,825                             | 3,365,887                              |  |
| Non-Controlling Interests            | -           | 291,415                               | 276,041                                | 2 206 025                             | 2 265 007                              |  |
| Total Equity                         | -           | 5,508,073                             | 5,378,233                              | 3,286,825                             | 3,365,887                              |  |
| Total Liabilities and Equity         | _           | 10,665,797                            | 10,693,368                             | 3,384,072                             | 3,389,263                              |  |

## C Condensed interim statements of changes in equity

# UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE PERIOD ENDED 30 JUNE 2025

|   | <> Attributable to Owners of the Company> Other |                  |                    |                    |                   |                      | >               | Non-                     |                 |
|---|---|------------------|--------------------|--------------------|-------------------|----------------------|-----------------|--------------------------|-----------------|
| <u>Group</u>  | Issued<br>Capital                               | Share<br>Premium | Treasury<br>Shares | Paid-in<br>Capital | Other<br>Reserves | Retained<br>Earnings | Total           | Controlling<br>Interests | Total<br>Equity |
| -   | <u>US\$'000</u>                                 | <u>US\$'000</u>  | <u>US\$'000</u>    | <u>US\$'000</u>    | <u>US\$'000</u>   | <u>US\$'000</u>      | <u>US\$'000</u> | <u>US\$'000</u>          | <u>US\$'000</u> |
| Balance at<br>1 Jan 2025  | 320,939   | 1,216,095        | (39,825)           | 184,318            | (421,839)         | 3,842,504            | 5,102,192       | 276,041                  | 5,378,233       |
| Profit for the period   | -   | -                | -                  | -                  | -                 | 160,259              | 160,259         | 13,328                   | 173,587         |
| Other comprehensive Income  | -   | -                | -                  | -                  | 32,544            | -                    | 32,544          | 20                       | 32,564          |
| Total comprehensive income for the period                               | -   | -                | -                  | -                  | 32,544            | 160,259              | 192,803         | 13,348                   | 206,151         |
| Dividends paid<br>(Note E18)  | -   | -                | -                  | -                  | -                 | (78,337)             | (78,337)        | -                        | (78,337)        |
| Dividends paid to non-controlling shareholders                          | -   | -                | -                  | -                  | -                 | -                    | -               | (402)                    | (402)           |
| Capital subscribed<br>by non-controlling<br>shareholders<br>(Note E21a) | -   | -                | -                  | -                  | -                 | -                    | -               | 2,428                    | 2,428           |
| Balance at<br>30 Jun 2025   | 320,939   | 1,216,095        | (39,825)           | 184,318            | (389,295)         | 3,924,426            | 5,216,658       | 291,415                  | 5,508,073       |
| Balance at<br>1 Jan 2024  | 320,939   | 1,216,095        | (39,825)           | 184,318            | (285,328)         | 3,530,202            | 4,926,401       | 253,503                  | 5,179,904       |
| Profit for the period   | -   | -                | -                  | -                  | -                 | 102,431              | 102,431         | 18,803                   | 121,234         |
| Other<br>comprehensive<br>loss  | -   | -                | -                  | -                  | (29,388)          | (17)                 | (29,405)        | (784)                    | (30,189)        |
| Total comprehensive (loss)/income for the period                        | -   | -                | -                  | -                  | (29,388)          | 102,414              | 73,026          | 18,019                   | 91,045          |
| Dividends paid<br>(Note E18)  | -   | -                | -                  | -                  | -                 | (57,337)             | (57,337)        | -                        | (57,337)        |
| Dividends paid to non-controlling shareholders                          | -   | -                | -                  | -                  | -                 | -                    | -               | (1,295)                  | (1,295)         |
| Balance at<br>30 Jun 2024   | 320,939   | 1,216,095        | (39,825)           | 184,318            | (314,716)         | 3,575,279            | 4,942,090       | 270,227                  | 5,212,317       |

## C Condensed interim statements of changes in equity (cont'd)

# UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (cont'd) FOR THE PERIOD ENDED 30 JUNE 2025

| Company   | Issued Capital US\$'000 | Share Premium US\$'000 | Treasury Shares US\$'000 | Other Reserves US\$'000 | Retained Earnings US\$'000 | Total<br>US\$'000 |
|---|-------------------------|------------------------|--------------------------|-------------------------|----------------------------|-------------------|
| Balance at 1 Jan 2025   | 320,939                 | 1,850,965              | (39,825)                 | (377,467)               | 1,611,275                  | 3,365,887         |
| Loss for the period, representing total comprehensive loss for the period     | -                       | -                      | -                        | -                       | (725)                      | (725)             |
| Dividends paid (Note E18)   | -                       | -                      | -                        | -                       | (78,337)                   | (78,337)          |
| Balance at 30 Jun 2025  | 320,939                 | 1,850,965              | (39,825)                 | (377,467)               | 1,532,213                  | 3,286,825         |
|   |                         |                        |                          |                         |                            |                   |
| Balance at 1 Jan 2024   | 320,939                 | 1,850,965              | (39,825)                 | (328,425)               | 1,669,777                  | 3,473,431         |
| Profit for the period, representing total comprehensive income for the period | -                       | -                      | -                        | -                       | 762                        | 762               |
| Dividends paid (Note E18)   | -                       | -                      | -                        | -                       | (57,337)                   | (57,337)          |
| Balance at 30 Jun 2024  | 320,939                 | 1,850,965              | (39,825)                 | (328,425)               | 1,613,202                  | 3,416,856         |

## D Condensed interim consolidated statements of cash flows

# UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2025

|  | 1st Half<br>2025<br>US\$'000 | 1st Half<br>2024<br>US\$'000 |
|--|------------------------------|------------------------------|
| Cash flows from operating activities                                       | <u>000 000</u>               | <u>000 000</u>               |
| Profit before tax  | 250,937                      | 156,615                      |
| Adjustments for:   |                              | ,                            |
| Depreciation   | 176,520                      | 173,801                      |
| Amortisation   | 4,293                        | 4,040                        |
| Net loss/(gain) from changes in fair value of biological assets            | 752                          | (8,924)                      |
| Unrealised foreign exchange loss   | 15,446                       | 37,839                       |
| Share of results of associated companies, net of tax                       | (2,258)                      | (3,710)                      |
| Share of results of joint ventures, net of tax                             | (13,640)                     | (6,940)                      |
| Gain on disposal of property, plant and equipment                          | (757)                        | (173)                        |
| Property, plant and equipment written off                                  | 442                          | 530                          |
| Allowance for/(Write-back of) impairment loss on inventories, net          | 1,247                        | (4,194)                      |
| Write-back of expected credit loss on trade receivables, net               | (380)                        | (451)                        |
| Trade receivables written off  | 271                          | -<br>-                       |
| Gain on disposal of a joint venture  | -                            | (32,030)                     |
| Changes in fair value of financial assets at fair value through            |                              |                              |
| profit or loss   | (821)                        | 2,765                        |
| Interest income  | (31,013)                     | (36,148)                     |
| Interest expense   | 109,829                      | 120,800                      |
| Operating cash flow before working capital changes                         | 510,868                      | 403,820                      |
| Changes in operating assets and liabilities:                               |                              |                              |
| Trade receivables  | (96,001)                     | (133,300)                    |
| Other current assets   | 125,506                      | (67,063)                     |
| Inventories  | (15,866)                     | 34,777                       |
| Trade and trust receipts payables  | 111,390                      | 7,886                        |
| Other payables   | 75,161                       | 44,984                       |
| Cash generated from operations   | 711,058                      | 291,104                      |
| Interest received  | 30,241                       | 41,489                       |
| Interest paid  | (106,122)                    | (121,678)                    |
| Tax paid   | (3,046)                      | (117,845)                    |
| Net cash generated from operating activities                               | 632,131                      | 93,070                       |
| Cash flows from investing activities                                       |                              |                              |
| Proceeds from disposal of property, plant and equipment                    | 1,468                        | 1,067                        |
| Proceeds from disposal of bearer plants                                    | 1,333                        | 310                          |
| Capital expenditure on property, plant and equipment                       | (160,574)                    | (104,374)                    |
| Capital expenditure on bearer plants                                       | (21,826)                     | (28,044)                     |
| Return of capital from/(Payments for) investments in financial assets, net | 49,036                       | (224,547)                    |
| Proceeds from Plasma/KKPA program plantations, net                         | -                            | 455                          |
| Proceeds from disposal of a joint venture                                  | -                            | 60,146                       |
| Return of capital from a joint venture                                     | 42                           | -                            |
| Dividend received from an associated company                               | 1,666                        | -                            |
| Dividend received from joint ventures                                      | -                            | 2,252                        |
| Payments for deferred expenditure and intangible assets                    | (11,197)                     | (833)                        |
| Net increase in long-term receivables and assets                           | (27,647)                     | (13,147)                     |
| Net cash used in investing activities                                      | (167,699)                    | (306,715)                    |

## D Condensed interim consolidated statements of cash flows (cont'd)

# **UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS** (cont'd) FOR THE PERIOD ENDED 30 JUNE 2025

|  | 1st Half        | 1st Half        |
|--|-----------------|-----------------|
|  | 2025            | 2024            |
|  | <u>US\$'000</u> | <u>US\$'000</u> |
| Cash flows from financing activities                                 |                 |                 |
| Proceeds from short-term borrowings                                  | 3,017,290       | 1,784,738       |
| Proceeds from long-term borrowings                                   | 30,000          | 746,394         |
| Payments of short-term borrowings                                    | (3,266,844)     | (1,962,607)     |
| Payments of long-term borrowings                                     | (79,337)        | (344,617)       |
| Payments of principal element of leases                              | (8,114)         | (9,982)         |
| Payments of bonds payable  | (48,322)        | (61,654)        |
| Payments of dividends  | (78,739)        | (58,632)        |
| Capital subscribed by non-controlling shareholders                   | 2,428           | -               |
| Payments of deferred loan charges and bank loan administration costs | (543)           | (3,278)         |
| (Increase)/Decrease in cash in banks and time deposits pledged       | (36,230)        | 66,232          |
| Net cash (used in)/generated from financing activities               | (468,411)       | 156,594         |
| Net decrease in cash and cash equivalents                            | (3,979)         | (57,051)        |
| Cash and cash equivalents at the beginning of the period             | 278,596         | 317,633         |
| Effect of exchange rate changes on cash and cash equivalents         | 2,786           | (7,791)         |
| Cash and cash equivalents at the end of the period (Note E9)         | 277,403         | 252,791         |

#### 1 Corporate information

Golden Agri-Resources Ltd (the "Company" or "GAR") is a public limited company incorporated in Mauritius. The registered office is c/o IQ EQ Corporate Services (Mauritius) Ltd, 33 Edith Cavell Street, Port Louis, 11324, Mauritius.

The Company is principally engaged as an investment holding company. The principal activities of the subsidiaries, associated companies and joint ventures are described in Note 47 to the consolidated financial statements for the financial statements for the year ended 31 December 2024. These condensed interim consolidated financial statements as at and for half year ended 30 June 2025 comprise the condensed financial statements of the Company and its subsidiaries (the "Group").

## 2 Basis of preparation

The condensed interim consolidated financial statements of the Group for half year ended 30 June 2025, have been prepared in accordance with International Accounting Standard ("IAS") 34. *Interim Financial Reporting*.

The condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements for the year ended 31 December 2024.

The condensed interim consolidated financial statements are presented in United States dollar, which is the Company's functional currency and presentation currency. All financial information presented in United States dollars have been rounded to the nearest thousand, unless otherwise stated.

#### 2.1 New and revised International Financial Reporting Standards ("IFRSs")

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with the IFRSs, except for the adoption of new and revised IFRSs effective for annual periods beginning on 1 January 2025. The adoption of the new and revised IFRSs has had no material financial impact on the condensed interim financial statements of the Group. The Group has not early adopted any new and revised IFRSs that have been issued but are not yet effective.

## 2.2 Use of judgement and estimates

In preparing the condensed interim financial statements, management has made judgements, estimates and assumptions that affect the application of the Group's accounting policies and the reported amounts of assets, liabilities, income and expenses. Although these estimates are based on management's best knowledge of current events and actions, actual results may differ from these estimates. The significant judgements made in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the year ended 31 December 2024.

Estimates and underlying assumptions are reviewed on an ongoing basis. Financial impact arising from revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

### 3 Seasonal operations

The production of fresh fruit bunch ("FFB") in oil palm plantations is subject to seasonal fluctuations as a result of weather conditions and rainfall patterns.

## 4 Segment and revenue information

| Sales in Indonesia   | Segment and revenue information |                       |                       |                |                 |
|--|---------------------------------|-----------------------|-----------------------|----------------|-----------------|
| Sales in Indonesia         US*1000         US*1000           Third parties         1,071,927         912,929           Associated companies         12,644         14,046           Joint ventures         15,641         88,464           Related parties         1,244-158         1,018,608           Sales outside Indonesia         1,244-158         1,018,608           Third parties         4,907,764         4,123,158           Related parties         4,907,764         4,123,193           Related parties         4,907,764         4,123,193           Related parties         8,090,764         4,123,193           Related parties         8,090,764         4,123,193           Related parties         8,090,764         4,123,193           Related parties         8,090,764         1,130,790         5,14,802           Related parties         1,300,900         1,100,900 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>   |                                 |                       |                       |                |                 |
| Sales in Indonesia         1,071,927         912,026           Associated companies         1,264         14,646           Joint ventures         15,641         88,464           Related parties         2,746         2,506           Sales outside Indonesia         4,907,764         4,123,158           Related parties         4,907,764         4,123,158           Related parties         4,907,764         4,123,193           Related parties         4,907,764         4,133,193           Related parties         4,908,908         1,130,790         5,141,802           Revenue from external customers         5,343         6,998,489  |                                 |                       |                       |                |                 |
| Tridiparties   1,071,927   912,929   Associated companies   1,071,927   14,646   14,646   156,841   14,646   12,746   1,018,689   1,2244,159   1,018,689   1,244,159   1,018,689   1,244,159   1,018,689   1,244,159   1,018,689   1,244,159   1,018,689   1,244,159   1,018,689   1,244,159   1,018,689   1,249,07,764   1,23,158   1,29,07,764   1,23,158   1,29,07,764   1,23,158   1,29,07,764   1,23,158   1,29,07,764   1,23,158   1,29,07,764   1,23,158   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,29,07,764   1,23,159   1,23,159   1,29,07,764   1,23,159   1,2 | Onlando Indonesia               |                       | <u>US</u>             | <u>5\$'000</u> | <u>US\$'000</u> |
|  |                                 |                       | 1.0                   | 71 027         | 012 020         |
| Related parties   1,2,46   2,746   2,766   1,018,089     Sales outside Indonesia   Third parties   2,407,764   4,123,158     Related parties   2,407,764   4,123,158     Related parties   2,407,764   4,123,158     Related parties   2,407,764   4,123,158     Related parties   2,407,764   4,123,153     Revenue from external customers   3,343   6,098,489   5,100     Revenue from external customers   53,433   6,098,489   6,151,922     Revenue from external customers   1,130,790   6,151,922     Revenue from external customers   2,258   1,59   6,66,250     Revenue from external customers   1,209   1,001   1,001   1,001     Revenue from external customers   1,200   1,001   1,001   1,001     Revenue from changes in fair value of financial assets at fair value through profit or loss   1,201   1,001   1,001   1,001     Revenue from changes in fair value of financial assets at fair value through profit or loss   1,201   1,201   1,201   1,201   1,201   1,201     Respect to profit of:   2,258   2,2  | •                               |                       | 1,0                   |                |                 |
| Related parties  | •                               |                       | 1                     |                |                 |
| Sales outside Indonesia         1,244,158         1,018,689           Third parties         4,907,764         4,123,158           Related parties         2,33         3,35           Related parties         2,4907,764         4,123,193           Plantations and palm palm palm palm palm palm palm palm   |                                 |                       | ı                     |                |                 |
| Sales outside Indonesia         4,907,764         4,123,158           Related parties         4,907,764         4,123,193           Related parties         4,907,764         4,123,193           Related parties         Palm tailons and palm optimality and others are partial customers         Palm tail tail tail tail tail tail tail tail   | Related parties                 |                       | 1.0                   |                |                 |
| Third parties Related parties         4,907,764 (4,907,764 (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,123,193) (4,907,764) (4,907,904) (4,907,764) (4,907,904                                | Calca autaida Indonesia         |                       |                       | 44,100         | 1,010,009       |
| Palmations   Pa  |                                 |                       | <i>1</i> C            | 007 764        | A 122 158       |
| Pantations and palm oli mills   Palm   Pal | •                               |                       | 4,8                   | -              |                 |
| Plantation and part of mexernal customers   53,433   6,098,489   1,130,790   6,151,922   1,202   1,130,790   1,  | Nelated parties                 |                       | 4.0                   |                |                 |
| Plantations of part   Plantations of part  |                                 |                       |                       | 07,704         | 4,125,195       |
| Ist Half 2025         and palm oil mills Us8'000         laurics and pustomers Us8'000         leliminations Us8'000         Total 28'000           Revenue from external customers Inter-segment sales         53,433         6,098,489         -         6,151,922           Inter-segment sales         1,130,790         -         (1,130,790)         -           Cotal revenue         1,184,223         6,098,489         (1,130,790)         6,151,922           EBITDA         320,406         245,685         159         566,250           Other information         Capital expenditure         88,290         90,765         -         179,055           Capital expenditure         88,290         90,765         -         179,055         182,400           Depreciation and amortisation         (124,496)         (56,317)         -         (180,813)           Write-back of expected credit loss on trade receivables, net         -         330         -         380           Write-back of expected credit loss on trade receivables writen off         (752)         -         -         (772)           Net loss from changes in fair value of biological assets         (180, 133)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         - <td< th=""><th></th><th></th><th>6,1</th><th>51,922</th><th>5,141,882</th></td<>   |                                 |                       | 6,1                   | 51,922         | 5,141,882       |
| Inter-segment sales  | <u>1st Half 2025</u>            | and palm<br>oil mills | laurics and<br>others |                |                 |
| Total revenue   1,184,223   6,098,489   (1,130,790)   6,151,922  | Revenue from external customers | 53,433                | 6,098,489             | -              | 6,151,922       |
| EBITDA         320,406         245,685         159         566,250           Other information         20,100         90,765         -         179,055           Capital expenditure         88,290         90,765         -         179,055           Unallocated capital expenditure         88,290         90,765         -         179,055           Unallocated capital expenditure         (56,317)         -         (180,813)           Write-back of expected credit loss on trade receivables, net         380         -         380           Trade receivables writen off         -         380         -         380           Trade receivables writen off         -         380         -         380           Trade receivables writen off         -         380         -         271           Net loss from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Assets         -         2,258         -         2,258           Segment in sets         4,361,799 <t< td=""><td>Inter-segment sales</td><td>1,130,790</td><td>-</td><td>(1,130,790)</td><td>-</td></t<>   | Inter-segment sales             | 1,130,790             | -                     | (1,130,790)    | -               |
| Other information         88,290         90,765         -         179,055           Unallocated capital expenditure         88,290         90,765         -         179,055           Unallocated capital expenditure         3,345           Total capital expenditure         (124,496)         (56,317)         -         (180,813)           Write-back of expected credit loss on trade receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         2,258           Joint ventures         -         2,258         2,258           Joint ventures         -         13,640         -         13,640           Nestest         -         26,837         -         28,066  | Total revenue                   | 1,184,223             | 6,098,489             | (1,130,790)    | 6,151,922       |
| Capital expenditure         88,290         90,765         -         179,055           Unallocated capital expenditure         3,345         3,345           Total capital expenditure         (124,496)         (56,317)         -         (180,813)           Depreciation and amortisation         (124,496)         (56,317)         -         (180,813)           Write-back of expected credit loss on trade receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         2,258           Associated companies         -         2,258         2,258           Joint ventures         -         2,854         (1,253,046)         8,996,239           Investment in:         -         260,655         -         260,655           Unallocated assets   | EBITDA                          | 320,406               | 245,685               | 159            | 566,250         |
| Capital expenditure         88,290         90,765         -         179,055           Unallocated capital expenditure         3,345         3,345           Total capital expenditure         (124,496)         (56,317)         -         (180,813)           Depreciation and amortisation         (124,496)         (56,317)         -         (180,813)           Write-back of expected credit loss on trade receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         2,258           Associated companies         -         2,258         2,258           Joint ventures         -         2,854         (1,253,046)         8,996,239           Investment in:         -         260,655         -         260,655           Unallocated assets   |                                 |                       |                       |                |                 |
| Depreciation and amortisation   (124,496)   (56,317)   (180,813)   | Other information               |                       |                       |                |                 |
| Total capital expenditure         182,400           Depreciation and amortisation         (124,496)         (56,317)         - (180,813)           Write-back of expected credit loss on trade receivables, net         - 380         - 380           Trade receivables written off         - (271)         - (271)           Net loss from changes in fair value of financial assets         (752)         - (271)         - (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         - 821           Interest on borrowings         (31,350)         (78,479)         - (109,829)           Share of profit of:         - 2,258         - 2,258           Associated companies         - 2,258         - 2,258           Joint ventures         - 13,640         - 13,640           Investment in:         - 260,655         - 28,066           Joint ventures         - 260,655         - 260,655           Unallocated assets         - 260,655         - 260,655           Unallocated assets         - 260,655         - 13,380,837           Total assets         - 260,655         - 260,655           Unallocated liabilities         - (628,364)         (4,027,012)         1,309,552         (3,345,824)  |                                 | 88,290                | 90,765                | -              | 179,055         |
| Depreciation and amortisation   (124,496)   (56,317)   - (180,813)   | Unallocated capital expenditure |                       |                       |                | 3,345           |
| Write-back of expected credit loss on trade receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Segment assets         4,361,799         5,887,486         (1,253,046)         8,996,239           Investment in:         -         260,655         -         28,066           Joint ventures         -         260,655         -         260,655           Unallocated assets         -         260,655         -         260,655           Unallocated assets         -         260,655         -         1,380,837           Total as  | Total capital expenditure       |                       |                       |                | 182,400         |
| Write-back of expected credit loss on trade receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Segment assets         4,361,799         5,887,486         (1,253,046)         8,996,239           Investment in:         -         260,655         -         28,066           Joint ventures         -         260,655         -         260,655           Unallocated assets         -         260,655         -         260,655           Unallocated assets         -         260,655         -         1,380,837           Total as  | <b></b>                         | (404 400)             | (50.047)              |                | (400.040)       |
| receivables, net         -         380         -         380           Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Joint ventures         -         13,640         -         13,640           Investment in:         -         26,837         -         28,066           Joint ventures         -         260,655         -         260,655           Unallocated assets         -         260,655         -         260,655           Unallocated assets         -         260,655         -         1,380,837           Total assets         -         260,655         -         10,665,797           Liabilities         -         (628,364)         <   | •                               | (124,496)             | (56,317)              | -              | (180,813)       |
| Trade receivables written off         -         (271)         -         (271)           Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Joint ventures         -         13,640         -         13,640           Assets         -         13,640         -         13,640           Investment in:         -         260,655         8,996,239           Investment in:         -         260,655         -         28,066           Joint ventures         1,229         26,837         -         28,066           Joint ventures         -         260,655         -         260,655           Unallocated assets         -         260,655         -         260,655           Segment liabilities         (628,364)         (4,027,012)         1,309,552         (3,345,824)           Unallocated liabilities         (628,364)  | ·                               |                       | 000                   |                | 000             |
| Net loss from changes in fair value of biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Associated companies         -         13,640         -         13,640           Joint ventures         -         13,640         -         13,640           Segment assets         4,361,799         5,887,486         (1,253,046)         8,996,239           Investment in:         -         260,655         -         28,066           Joint ventures         1,229         26,837         -         260,655           Unallocated assets         -         260,655         -         260,655           Unallocated assets         -         260,655         -         1,380,837           Total assets         -         260,655         -         260,655           Unallocated liabilities         (628,364)         (4,027,012)         1,309,552         (3,345,824)           Unallocated l  |                                 | -                     |                       | -              |                 |
| biological assets         (752)         -         -         (752)           (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss         (180)         1,001         -         821           Interest on borrowings         (31,350)         (78,479)         -         (109,829)           Share of profit of:         -         2,258         -         2,258           Joint ventures         -         2,258         -         2,258           Joint ventures         -         13,640         -         13,640           Assets         -         4,361,799         5,887,486         (1,253,046)         8,996,239           Investment in:         -         260,655         -         28,066           Joint ventures         1,229         26,837         -         260,655           Unallocated assets         -         260,655         -         260,655           Unallocated assets         -         260,655         -         1,380,837           Total assets         -         260,655         -         10,665,797           Liabilities         -         4,027,012         1,309,552         (3,345,824)           Unallocated liabilities         (4,027,012) <t< td=""><td></td><td>-</td><td>(2/1)</td><td>-</td><td>(271)</td></t<>   |                                 | -                     | (2/1)                 | -              | (271)           |
| (Loss)/Gain from changes in fair value of financial assets at fair value through profit or loss       (180)       1,001       -       821         Interest on borrowings       (31,350)       (78,479)       -       (109,829)         Share of profit of:       -       -       2,258       -       2,258         Joint ventures       -       13,640       -       13,640         Assets       -       13,640       -       13,640         Assets       -       13,640       -       13,640         Investment assets       4,361,799       5,887,486       (1,253,046)       8,996,239         Investment in:       -       260,655       -       28,066         Joint ventures       1,229       26,837       -       260,655         Unallocated assets       -       260,655       -       260,655         Unallocated assets       1,380,837       10,665,797         Liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)   | <u> </u>                        | (750)                 |                       |                | (750)           |
| assets at fair value through profit or loss       (180)       1,001       -       821         Interest on borrowings       (31,350)       (78,479)       -       (109,829)         Share of profit of:       The special speci   |                                 | (752)                 | -                     | -              | (752)           |
| Interest on borrowings       (31,350)       (78,479)       -       (109,829)         Share of profit of:   |                                 | (190)                 | 1 001                 |                | 921             |
| Share of profit of:         Associated companies       -       2,258       -       2,258         Joint ventures       -       13,640       -       13,640             Assets         Segment assets       4,361,799       5,887,486       (1,253,046)       8,996,239         Investment in:         Associated companies       1,229       26,837       -       28,066         Joint ventures       -       260,655       -       260,655         Unallocated assets       1,380,837         Total assets       10,665,797         Liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)  |                                 |                       |                       | -              |                 |
| Associated companies     Joint ventures     - 2,258  |                                 | (31,330)              | (10,419)              | _              | (109,029)       |
| Assets         4,361,799         5,887,486         (1,253,046)         8,996,239           Investment in:         4,361,799         26,837         -         28,066           Joint ventures         1,229         26,837         -         260,655           Unallocated assets         1,380,837         10,665,797         10,665,797           Liabilities         Segment liabilities         (628,364)         (4,027,012)         1,309,552         (3,345,824)           Unallocated liabilities         (1,811,900)         (1,811,900)         (3,811,900)   | •                               | _                     | 2 258                 | _              | 2 258           |
| Assets         Segment assets       4,361,799       5,887,486       (1,253,046)       8,996,239         Investment in:       Associated companies       1,229       26,837       -       28,066         Joint ventures       -       260,655       -       260,655         Unallocated assets       1,380,837       -       10,665,797         Liabilities       Segment liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)   |                                 | _                     |                       | _              |                 |
| Segment assets       4,361,799       5,887,486       (1,253,046)       8,996,239         Investment in:       Associated companies       1,229       26,837       -       28,066         Joint ventures       -       260,655       -       260,655         Unallocated assets       1,380,837       10,665,797         Total assets       10,665,797         Liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)  | Come volkaroo                   |                       | 10,010                |                | 10,010          |
| Segment assets       4,361,799       5,887,486       (1,253,046)       8,996,239         Investment in:       Associated companies       1,229       26,837       -       28,066         Joint ventures       -       260,655       -       260,655         Unallocated assets       1,380,837       10,665,797         Total assets       10,665,797         Liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)  | Assets                          |                       |                       |                |                 |
| Investment in:         Associated companies       1,229       26,837       -       28,066         Joint ventures       -       260,655       -       260,655         Unallocated assets       1,380,837         Total assets       10,665,797         Liabilities       Segment liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)  |                                 | 4,361,799             | 5,887,486             | (1,253,046)    | 8,996,239       |
| Joint ventures       - 260,655       - 260,655         Unallocated assets       1,380,837         Total assets       10,665,797         Liabilities       Segment liabilities       (628,364) (4,027,012) 1,309,552 (3,345,824)         Unallocated liabilities       (1,811,900)  | -                               |                       | , ,                   | , , ,          |                 |
| Joint ventures       - 260,655       - 260,655         Unallocated assets       1,380,837         Total assets       10,665,797         Liabilities       Segment liabilities       (628,364) (4,027,012) 1,309,552 (3,345,824)         Unallocated liabilities       (1,811,900)  | Associated companies            | 1,229                 | 26,837                | -              | 28,066          |
| Unallocated assets         1,380,837           Total assets         10,665,797           Liabilities         Segment liabilities         (628,364) (4,027,012) 1,309,552 (3,345,824) (1,811,900)           Unallocated liabilities         (1,811,900)   | •                               | · -                   |                       | -              |                 |
| Liabilities         (628,364)         (4,027,012)         1,309,552         (3,345,824)           Unallocated liabilities         (1,811,900)  | Unallocated assets              |                       |                       |                |                 |
| <u>Liabilities</u> Segment liabilities (628,364) (4,027,012) 1,309,552 (3,345,824) Unallocated liabilities (1,811,900)   |                                 |                       |                       |                |                 |
| Segment liabilities       (628,364)       (4,027,012)       1,309,552       (3,345,824)         Unallocated liabilities       (1,811,900)  |                                 |                       |                       |                |                 |
| Unallocated liabilities (1,811,900)  |                                 |                       |                       |                |                 |
|  | -                               | (628,364)             | (4,027,012)           | 1,309,552      |                 |
| Total liabilities (5,157,724)  |                                 |                       |                       |                |                 |
|  | Total liabilities               |                       |                       |                | (5,157,724)     |

## 4 Segment and revenue information (cont'd)

| 1st Half 2024  | Plantations<br>and palm<br>oil mills<br>US\$'000 | Palm,<br>laurics and<br><u>others</u><br><u>US\$'000</u> | Eliminations<br>US\$'000 | <u>Total</u><br>US\$'000 |
|--|--|--|--------------------------|--------------------------|
| Revenue from external customers  | 48,484   | 5,093,398  | -                        | 5,141,882                |
| Inter-segment sales  | 859,348  | -  | (859,348)                |                          |
| Total revenue  | 907,832  | 5,093,398  | (859,348)                | 5,141,882                |
| EBITDA   | 212,633  | 281,771  | 202                      | 494,606                  |
| Other information  |  |  |                          |                          |
| Capital expenditure  | 89,309   | 42,016   | -                        | 131,325                  |
| Unallocated capital expenditure  |  |  |                          | 1,093                    |
| Total capital expenditure  |  |  |                          | 132,418                  |
| Depreciation and amortisation Write-back of expected credit loss on trade                | (121,333)  | (56,508)   | -                        | (177,841)                |
| receivables, net   | -  | 451  | -                        | 451                      |
| Gain on disposal of a joint venture  | -  | 32,030   | -                        | 32,030                   |
| Net gain from changes in fair value of   |  |  |                          |                          |
| biological assets  | 8,924  | -  | -                        | 8,924                    |
| Loss from changes in fair value of financial assets at fair value through profit or loss | (465)  | (2,300)  | _                        | (2,765)                  |
| Interest on borrowings   | (45,869)   | (74,931)   | -                        | (120,800)                |
| Share of profit of:  | (10,000)   | (1.1,001)  |                          | (:=0,000)                |
| Associated companies   | 31   | 3,679  | -                        | 3,710                    |
| Joint ventures   |  | 6,940  | -                        | 6,940                    |

The following is an analysis of revenue and based on geographical location of customers:

|                      | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> |
|----------------------|-------------------------------------|-------------------------------------|
| China                | 466,155                             | 431,272                             |
| Indonesia            | 1,244,158                           | 1,018,689                           |
| India                | 875,332                             | 789,800                             |
| Rest of Asia         | 1,765,005                           | 1,407,949                           |
| Europe               | 929,110                             | 744,476                             |
| Others               | 872,162                             | 749,696                             |
| Consolidated revenue | 6,151,922                           | 5,141,882                           |

The following is an analysis of the carrying amount of non-current non-financial assets, analysed by the geographical areas in which the assets are located:

|  | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br><u>US\$'000</u> |
|--|------------------------------|-------------------------------|
| Indonesia                              | 3,986,613                    | 3,930,017                     |
| China                                  | 69,000                       | 68,884                        |
| Singapore                              | 157,964                      | 155,348                       |
| India                                  | 74,098                       | 69,938                        |
| Others                                 | 72,054                       | 75,184                        |
| Total non-current non-financial assets | 4,359,729                    | 4,299,371                     |

## 5 Profit before tax

Significant items not disclosed elsewhere in condensed interim consolidated financial statements:

|   | 1st Half<br>2025 | 1st Half<br>2024 |  |
|---|------------------|------------------|--|
|   | <u>US\$'000</u>  | <u>US\$'000</u>  |  |
| Depreciation of property, plant and equipment                     | (123,302)        | (122,552)        |  |
| Depreciation of bearer plants                                     | (53,215)         | (51,246)         |  |
| Depreciation of investment properties                             | (3)              | (3)              |  |
| Gain on disposal of property, plant and equipment                 | 757              | 173              |  |
| Gain on disposal of a joint venture                               | -                | 32,030           |  |
| Property, plant and equipment written off                         | (442)            | (530)            |  |
| Write-back of expected credit loss on trade receivables, net      | 380              | 451              |  |
| (Allowance for)/Write-back of impairment loss on inventories*     | (1,247)          | 4,194            |  |
| Investment income   | 6,078            | 752              |  |
| Gain/(Loss) on changes in fair value of financial assets at FVTPL | 821              | (2,765)          |  |

<sup>\*</sup> Allowance for impairment loss was made and charged to cost of sales as the carrying amount of certain inventories was higher than the net realisable value. Write-back of impairment loss was made as a result of an increase in net realisable value of certain inventories.

## Related party transactions

|  | 1st Half<br>2025 | 1st Half<br>2024 |
|--|------------------|------------------|
|  | US\$'000         | US\$'000         |
| (i) Sale of services   |                  | · <del></del>    |
| Rental income from related parties                               | 134              | 195              |
| Rental income from joint ventures                                | 486              | 55               |
| Sales of non-palm based product to a joint venture               | 847              | 268              |
| (ii) Purchase of goods and services                              |                  |                  |
| Insurance premium to a related party                             | 3,670            | 3,313            |
| Purchase of non-palm based products and services from related    |                  |                  |
| parties  | 26,866           | 45,843           |
| Purchase of palm based products and services from joint ventures | 39,365           | 18,243           |
| Freight and related expenses to joint ventures                   | 6,317            | 6,589            |
| Rental expense to a joint venture                                | 122              | -                |
| Rental and service charge expense to related parties             | 3,165            | 3,627            |
| (iii) Dividend income from:                                      |                  |                  |
| - joint ventures   | -                | 2,252            |
| - an associated company  | 1,666            |                  |

## 6 Income tax

|                     | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> |
|---------------------|-------------------------------------|-------------------------------------|
| Current income tax  | 81,091                              | 38,346                              |
| Deferred income tax | (3,741)                             | (2,965)                             |
|                     | 77,350                              | 35,381                              |

## 7 Earnings per share

Earnings per ordinary share for the period:

- (i) Based on weighted average number of ordinary shares
- Weighted average numbers of shares
- (ii) On a fully diluted basis
- Weighted average numbers of shares

| 0.81cents  |
|------------|
| 1,673,056  |
| applicable |
| applicable |
|            |

## 8 Net asset value per share

Net asset value per ordinary share based on existing issued share capital of 12,681,673,056 shares

| Gro             | oup                 | Com             | pany                |
|-----------------|---------------------|-----------------|---------------------|
| As at 30/6/2025 | As at<br>31/12/2024 | As at 30/6/2025 | As at<br>31/12/2024 |
| US\$0.43        | US\$0.42            | US\$0.26        | US\$0.27            |

## 9 Cash and cash equivalents

|   | Group                        |                               |  |
|---|------------------------------|-------------------------------|--|
|   | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br><u>US\$'000</u> |  |
| Time deposits, cash and bank balances                                 | 470,961                      | 435,924                       |  |
| Less: Cash in banks and time deposits pledged                         | (193,558)                    | (157,328)                     |  |
| Cash and cash equivalents in the consolidated statement of cash flows | 277,403                      | 278,596                       |  |

#### 10 Short-term investments

|                                    | Group                        |                               |  |
|------------------------------------|------------------------------|-------------------------------|--|
|                                    | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br><u>US\$'000</u> |  |
| Time deposits                      | 527,136                      | 557,959                       |  |
| Equity securities at FVOCI         | 116                          | 118                           |  |
| Financial assets at FVTPL:         |                              |                               |  |
| Equity securities held for trading | 13,763                       | 4,011                         |  |
| Debt securities held for trading   | 33,565                       | 1,815                         |  |
|                                    | 47,328                       | 5,826                         |  |
|                                    | 574,580                      | 563,903                       |  |

## 11 Other current assets

|                                      | Group                 |                               | Com                   | pany                   |
|--------------------------------------|-----------------------|-------------------------------|-----------------------|------------------------|
|                                      | 30/6/2025<br>US\$'000 | 31/12/2024<br><u>US\$'000</u> | 30/6/2025<br>US\$'000 | 31/12/2024<br>US\$'000 |
| Prepaid expenses                     | 51,826                | 18,051                        | 27                    | 26                     |
| Prepaid taxes                        | 158,673               | 186,751                       | -                     | -                      |
| Deposits and advances to suppliers   | 203,124               | 252,934                       | -                     | -                      |
| Derivative receivable                | 14,731                | 114,001                       | -                     | -                      |
| Others                               | 145,835               | 153,075                       | 91                    | 85                     |
|                                      | 574,189               | 724,812                       | 118                   | 111                    |
| Receivable from joint ventures       | 574                   | 2,072                         | -                     | -                      |
| Receivable from associated companies | 1,234                 | 2,956                         | -                     | -                      |
| Receivable from related parties      | 52                    | 54                            | -                     | -                      |
| Receivable from subsidiaries         | -                     |                               | 5,903                 | 5,905                  |
| _                                    | 576,049               | 729,894                       | 6,021                 | 6,016                  |

## 12 Long-term receivables and assets

|                                  | Group                 |                        | Company               |                        |
|----------------------------------|-----------------------|------------------------|-----------------------|------------------------|
|                                  | 30/6/2025<br>US\$'000 | 31/12/2024<br>US\$'000 | 30/6/2025<br>US\$'000 | 31/12/2024<br>US\$'000 |
| Loans receivable from associated |                       |                        |                       |                        |
| companies                        | 2,549                 | 703                    | -                     | -                      |
| Advances for projects            | 41,186                | 23,382                 | -                     | -                      |
| Land clearing                    | 9,996                 | 8,744                  | -                     | -                      |
| Advances for investment in land  | 1,495                 | 1,495                  | -                     | -                      |
| Others                           | 10,349                | 14,776                 | -                     | -                      |
|                                  | 65,575                | 49,100                 |                       | -                      |

## 13 Long-term investments

|                             | Gr                    | Group                  |                       | pany                          |
|-----------------------------|-----------------------|------------------------|-----------------------|-------------------------------|
|                             | 30/6/2025<br>US\$'000 | 31/12/2024<br>US\$'000 | 30/6/2025<br>US\$'000 | 31/12/2024<br><u>US\$'000</u> |
| Equity securities at FVOCI  | 959,091               | 939,829                | 224,457               | 229,457                       |
| Financial assets at FVTPL:  |                       |                        |                       |                               |
| Equity/Fund securities      | 301,637               | 356,843                | -                     | -                             |
| Convertible debt securities | 188,320               | 188,320                |                       |                               |
|                             | 1,449,048             | 1,484,992              | 224,457               | 229,457                       |

## 14 Other payables

|                            | Gr                           | oup                           | Com                          | mpany                  |  |
|----------------------------|------------------------------|-------------------------------|------------------------------|------------------------|--|
|                            | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br><u>US\$'000</u> | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br>US\$'000 |  |
| Advances and deposits      | 162,172                      | 127,811                       | -                            | -                      |  |
| Accrued expenses           | 202,846                      | 158,237                       | 142                          | 2,020                  |  |
| Payable to third parties   | 105,248                      | 88,298                        | -                            | -                      |  |
| Derivative payable         | 29,227                       | 36,647                        | -                            | -                      |  |
| Put option liability       | 79,395                       | 79,395                        | -                            | -                      |  |
| Others                     | 84,326                       | 81,833                        | 7                            | 6                      |  |
|                            | 663,214                      | 572,221                       | 149                          | 2,026                  |  |
| Payable to related parties | 345                          | 886                           | 5,272                        | 3,009                  |  |
|                            | 663,559                      | 573,107                       | 5,421                        | 5,035                  |  |

## 15 Borrowings

|                         | Gro             | oup             |
|-------------------------|-----------------|-----------------|
|                         | 30/6/2025       | 31/12/2024      |
|                         | <u>US\$'000</u> | <u>US\$'000</u> |
| Current liabilities     |                 |                 |
| Short-term borrowings   | 1,768,841       | 1,838,436       |
| Bonds and notes payable | 98,883          | 116,084         |
| Lease liabilities       | 15,468          | 16,736          |
|                         | 1,883,192       | 1,971,256       |
| Non-current liabilities |                 |                 |
| Long-term borrowings    | 1,254,830       | 1,470,649       |
| Bonds and notes payable | 181,435         | 213,935         |
| Lease liabilities       | 45,691          | 49,679          |
|                         | 1,481,956       | 1,734,263       |
|                         | 3,365,148       | 3,705,519       |

|   |           | 30/6/2025<br><u>US\$'000</u> |           |           | 31/12/2024<br><u>US\$'000</u> |           |
|---|-----------|------------------------------|-----------|-----------|-------------------------------|-----------|
|   | Secured   | Unsecured                    | Total     | Secured   | Unsecured                     | Total     |
| Amount repayable in one year or less Amount repayable after | 1,492,884 | 390,308                      | 1,883,192 | 1,430,149 | 541,107                       | 1,971,256 |
| one year  | 1,128,027 | 353,929                      | 1,481,956 | 1,314,057 | 420,206                       | 1,734,263 |
| Total   | 2,620,911 | 744,237                      | 3,365,148 | 2,744,206 | 961,313                       | 3,705,519 |

The secured borrowings are collaterised by certain cash and cash equivalents, short-term investments, inventories, trade receivables, bearer plants and property, plant and equipment.

## 16 Long-term payables and liabilities

|                                    | Gr                           | oup                           |
|------------------------------------|------------------------------|-------------------------------|
|                                    | 30/6/2025<br><u>US\$'000</u> | 31/12/2024<br><u>US\$'000</u> |
| Post-employment benefits liability | 84,105                       | 72,935                        |
| Rental deposits                    | 1,242                        | 1,264                         |
| Advance received                   | 121,000                      | 140,000                       |
| Derivative payable                 | 609                          | 1,168                         |
|                                    | 206,956                      | 215,367                       |

The above advance relates to advances received from customers pursuant to agreements to supply crude palm oil to the customers over a period of more than 12 months after the end of the reporting period.

#### 17 Issued capital and treasury shares

|                                 | No. of ordinary shares |               | <u>Amount</u>   |                 |
|---------------------------------|------------------------|---------------|-----------------|-----------------|
|                                 | Issued                 | Treasury      | Issued          | Treasury        |
| <b>Group and Company</b>        | capital                | shares        | capital         | shares          |
|                                 |                        |               | <u>US\$'000</u> | <u>US\$'000</u> |
| Issued and fully paid:          |                        |               |                 |                 |
| Balance at 31 December 2024 and |                        |               |                 |                 |
| 30 June 2025                    | 12,837,548,556         | (155,875,500) | 320,939         | (39,825)        |

There were no movements in the Company's issued capital since 30 June 2024.

#### 18 Dividends paid

| Group and Company Final dividend paid in respect of previous year of S\$0.00804 | 1st Half<br>2025<br><u>US\$'000</u> | 1st Half<br>2024<br><u>US\$'000</u> |
|---|-------------------------------------|-------------------------------------|
| (1H2024: S\$0.00613) per share  | 78,337                              | 57,337                              |

## 19 Financial instruments

## Fair Value of Financial Instruments

The carrying amounts of financial assets and liabilities with a maturity of less than one year, which include cash and cash equivalents, time deposits, short-term investments, trade and other receivables, trade and other payables and short-term interest-bearing borrowings are assumed to approximate their fair values due to their short-term maturities.

The fair values of long-term receivables and long-term interest-bearing borrowings are calculated based on discounted expected future principal and interest cash flows. The discount rates used are based on market rates for similar instruments at the end of the reporting period. As at 30 June 2025 and 31 December 2024, the carrying amounts of the long-term receivables and long-term interest-bearing borrowings approximate their fair values.

### Fair Value Hierarchy

The following table presents financial assets and financial liabilities measured at fair value on a recurring basis and classified by level of the following fair value measurement hierarchy:

- (a) Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities;
- (b) Level 2: inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is as prices) or indirectly (i.e. derived from prices); and
- (c) Level 3: inputs for the asset or liability that are not based on observable market data (unobservable inputs).

|  | Level 1         | Level 2         | Level 3         | Total           |
|--|-----------------|-----------------|-----------------|-----------------|
|  | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> | <u>US\$'000</u> |
| At 30 June 2025                            |                 |                 |                 |                 |
| Financial assets at FVOCI (Equity)         | -               | -               | 959,207         | 959,207         |
| Financial assets at FVTPL held for trading | 4,094           | 93,206          | 439,985         | 537,285         |
| Derivative receivable                      | -               | 14,731          | -               | 14,731          |
| Derivative payable                         |                 | (29,836)        | -               | (29,836)        |
|  | 4,094           | 78,101          | 1,399,192       | 1,481,387       |
| At 31 December 2024                        |                 |                 |                 |                 |
| Financial assets at FVOCI (Equity)         | -               | -               | 939,947         | 939,947         |
| Financial assets at FVTPL held for trading | 3,650           | 50,139          | 497,200         | 550,989         |
| Derivative receivable                      | -               | 114,001         | -               | 114,001         |
| Derivative payable                         |                 | (37,815)        | -               | (37,815)        |
|  | 3,650           | 126,325         | 1,437,147       | 1,567,122       |

#### **19** Financial instruments (cont'd)

#### Methods and Assumptions Used to Determine Fair Values

The methods and assumptions used by management to determine fair values are as follows:

## (i) Level 1 fair value measurements

The fair value of securities traded in active markets is based on quoted market prices at the reporting date.

## (ii) Level 2 fair value measurements

Fair value of forward currency contracts is calculated by reference to current forward exchange rates for contracts with similar maturity profiles as at the reporting date. The fair value of unquoted debt and equity securities and interest rate swap contracts is determined by reference to statements provided by external fund managers/financial institutions. For commodity futures contracts, observable prices are used as a measure of fair values for the outstanding contracts. For firm commitment contracts, the fair values are based on market prices and management's best estimate and are arrived at by reference to the market prices of another contract that is substantively similar and adjusted for premium or discount where relevant.

#### (iii) Level 3 fair value measurements

The fair values of financial assets classified under Level 3 of the fair value hierarchy were determined by reference to fund statements provided by external fund managers and valuation reports prepared by independent professional valuers. Valuation techniques included:

- Net present value method Fair value was determined by reference to valuations performed using the net
  present value method on its underlying assets, adjusted for the external borrowings. Forecasts of future cash
  flows are based on historical results, growth rate using industry trends, discount rate based on capital fund
  structure, general market and economic conditions.
- Fund statements Fair value was made with reference to the fund statements provided by external fund
  managers. The fund managers determined the fair value of its entire portfolio using multiple valuation
  techniques including price of recent transactions, Backsolve and option pricing model, Monte Carlo
  simulation, adjusted net assets value and discounted cash flow method of the investee companies.

During the current financial period, a net gain of US\$0.8 million (1H2024: net loss of US\$2.8 million) was recognised in the consolidated income statement due to changes in fair value. There were no transfers between Level 1, 2 and 3 during the current financial period. Movements in Level 3 financial assets measured at fair value are as follows:

| Financial<br>assets at<br><u>FVOCI</u><br><u>US\$'000</u> | Financial<br>assets at<br><u>FVTPL</u><br><u>US\$'000</u>    |
|---|--|
| 939,947   | 497,200  |
| 21,896  | -  |
| -   | (573)  |
| (2,661)   | (56,642)   |
| 25  |  |
| 959,207   | 439,985  |
|   | FVOCI<br>US\$'000<br>939,947<br>21,896<br>-<br>(2,661)<br>25 |

#### 20 Significant capital expenditure commitments

At the end of the reporting period, the estimated significant expenditure committed but not provided for in the consolidated financial statements amounted to US\$188.641,000 (31.12.2024: US\$172,706,000).

## 21 Changes in ownership interests in subsidiaries during the current financial year

- (a) In March 2025, GEF Foods India Private Limited ("GEF"), a subsidiary held by a non-wholly owned intermediate holding company, issued new shares to non-controlling shareholders for a consideration of INR210,000,000 (equivalent to US\$2,428,000). Following this transaction, the Group's effective interest in GEF decreased from 56.27% to 39.39%.
- (b) In May 2025, Golden Americas Pte. Ltd. was struck off. There was no significant financial impact arising from this struck off.

## F Other information required by Listing Rule Appendix 7.2

#### 1 Review

The condensed interim consolidated statement of financial position of Golden Agri-Resources Ltd (the "Company") and its subsidiaries as at 30 June 2025 and the related condensed consolidated income statements and statement of other comprehensive income, condensed statement of changes in equity and condensed statement of cash flows for the half year then ended and certain explanatory notes have not been audited or reviewed.

## 2 Review of performance of the Group

|                                | 1st Half 2025<br><u>US\$'000</u> | 1st Half 2024<br><u>US\$'000</u> | Change<br><u>%</u> |
|--------------------------------|----------------------------------|----------------------------------|--------------------|
| Revenue by segment             |                                  |                                  |                    |
| Plantations and palm oil mills | 1,184,223                        | 907,832                          | 30.4               |
| Palm, laurics and others       | 6,098,489                        | 5,093,398                        | 19.7               |
| Inter-segment eliminations     | (1,130,790)                      | (859,348)                        | 31.6               |
| Total Revenue                  | 6,151,922                        | 5,141,882                        | 19.6               |
| EBITDA by segment              |                                  |                                  |                    |
| Plantations and palm oil mills | 320,406                          | 212,633                          | 50.7               |
| Palm, laurics and others       | 245,685                          | 281,771                          | (12.8)             |
| Inter-segment eliminations     | 159                              | 202                              | (21.3)             |
| Total EBITDA                   | 566,250                          | 494,606                          | 14.5               |

#### Notes:

(2) Plantations and palm oil mills segment refers to products from upstream business.

<sup>(1)</sup> EBITDA refers to earnings before tax, non-controlling interests, interest on borrowings, depreciation and amortisation, net (loss)/gain from changes in fair value of biological assets and foreign exchange loss.

<sup>(3)</sup> Palm, laurics and others segment refers to the processing and global merchandising of palm and oilseed-based products comprising bulk and branded products, oleochemicals, sugar and other vegetable oils.

#### F Other information required by Listing Rule Appendix 7.2 (cont'd)

#### **REVIEW OF PERFORMANCE FOR HALF YEAR ENDED 30 JUNE 2025**

Revenue for the Group grew 19.6% to US\$6,151.9 million for the half year ended 30 June 2025 ("1H2025"), as compared to US\$5,141.9 million for the previous corresponding period ("1H2024"). This was driven by improved plantation output and higher crude palm oil (CPO) prices. Consequently, underlying profit and net profit attributable to owners of the Company were higher at US\$232.5 million and US\$160.3 million, respectively for the current period, up from US\$188.7 million and US\$102.4 million, respectively in 1H2024.

#### PLANTATIONS AND PALM OIL MILLS

Revenue from our plantation and palm oil mills segment rose by 30.4% to US\$1,184.2 million in 1H2025, while EBITDA increased by 50.7% to US\$320.4 million in the current period. This was primarily driven by a recovery of plantation output and higher CPO prices during the current period. The average international CPO price (FOB Belawan) for the current period was US\$1,090 per tonne, representing an 18.8% increased as compared to US\$917 per tonne in 1H2024.

Our fresh fruit bunch ("FFB") and palm product output for 1H2025 were higher at 4,364,000 tonnes and 1,318,000 tonnes, respectively as compared to 3,970,000 tonnes and 1,207,000 tonnes, respectively in 1H2024. This recovery was mainly attributable to the easing impact of El Niño phenomenon, despite ongoing preparation of our old estates for replanting.

#### PALM, LAURICS AND OTHERS

Our palm, laurics and others segment refers to the processing and global merchandising of palm and oilseed-based products comprising bulk and branded products, oleochemicals, sugar and other vegetable oils.

Revenue from our palm, laurics and others segment was 19.7% higher at US\$6,098.5 million in 1H2025 largely attributable to higher commodity prices. However, the segment's EBITDA was US\$245.7 million in 1H2025, a decline from US\$281.8 million in 1H2024, as margins came under pressure amid a highly competitive market environment and slowing global economic conditions.

#### FINANCIAL EXPENSES, NET

Net financial expenses comprised net interest expenses (after deducting interest income), amortisation of deferred loan charges and other finance charges. Net financial expenses decreased from US\$86.0 million in 1H2024 to US\$82.1 million in the current period mainly due to lower total average borrowings.

## SHARE OF RESULTS OF JOINT VENTURES, NET

The Group's share of profit in joint ventures increased from US\$6.9 million in 1H2024 to US\$13.6 million mainly attributable to better operating performance in a joint venture in line with the higher market prices during the current period.

#### **FOREIGN EXCHANGE LOSS**

The Group recorded net foreign exchange loss of US\$23.9 million in 1H2025, a 50.5% decrease from US\$48.3 million in 1H2024. The current period's loss was mainly attributable to fair value loss on forward foreign currency contracts entered to hedge the currency exposure.

### **OTHER INCOME**

Net other income comprised mainly changes in fair value of biological assets (agricultural produce) and financial assets, income from sales of seedlings and other materials, investment income/gain as well as rental income, net of provision for expected credit loss on receivables and impairment losses, if any. Net other income was lower at US\$7.7 million in the current period as compared to US\$46.0 million in 1H2024 as the comparatives included a non-recurring gain on disposal of a joint venture of US\$32.0 million.

#### F Other information required by Listing Rule Appendix 7.2 (cont'd)

#### TAX

Income tax comprised provision for current and deferred income tax derived by applying the varying statutory tax rates of the different countries in which the Group operates on its taxable profit and taxable temporary difference. No group relief is available for set-off of taxable profits against tax losses of companies within the Group. Net tax expense was higher at US\$77.4 million in the current period mainly due to higher taxable profit recorded in certain subsidiaries.

#### **REVIEW OF FINANCIAL POSITION AS AT 30 JUNE 2025**

#### **ASSETS**

The Group's total assets decreased marginally from US\$10,693.4 million as at the end of 2024 to US\$10,665.8 million as at 30 June 2025.

Trade receivables increased by US\$96.1 million to US\$981.6 million as at end June 2025, mainly driven by higher commodity market prices.

Other current assets decreased by US\$153.8 million to US\$576.0 million as at end June 2025 mainly due to lower derivative receivables resulting from forward foreign currency contracts and lower advances paid to suppliers.

Total non-current assets decreased from US\$6,041.9 million to US\$6,012.6 million as at 30 June 2025 largely attributable to reduction in long-term investment due to return of investment received.

#### **LIABILITIES**

Total liabilities of the Group decreased from US\$5,315.1 million as at end 2024 to US\$5,157.7 million as at 30 June 2025 mainly due to lower borrowings following repayment made during 1H2025, partially offset by increases in trust receipts payable and accrued operating expenses.

### **REVIEW OF CASH FLOWS FOR HALF YEAR ENDED 30 JUNE 2025**

The Group recorded a higher net cash generated from operating activities of US\$632.1 million in the current period, as compared to US\$93.1 million in 1H2024. This was mainly due to better operating performance, cash inflows from changes in working capital, as well as lower tax payment following the refund received during the current period.

Net cash used in investing activities of US\$167.7 million was mainly related to capital expenditure incurred for our plantations, and property, plant and equipment, partially offset by return of investments received during the current period.

Net cash used in financing activities of US\$468.4 million was mainly related to repayment of borrowings (net of proceeds) and dividend payment made during the current period.

Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results

Not applicable.

- F Other information required by Listing Rule Appendix 7.2 (cont'd)
- 3A Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion, (a) updates on the efforts taken to resolve each outstanding audit issue; (b) confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed. This is not required for any audit issue that is a material uncertainty relating to going concern

Not applicable.

A commentary at the date of the announcement of the competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months

The global vegetable oil market outlook remains volatile, influenced by sustained geopolitical tensions, uncertain economic conditions across key markets, and climate variability. Despite this, CPO prices were robust in the current period and the near-term outlook remains positive, underpinned by resilient demand for food and biofuels and limited expansion in palm oil planting areas. The Group remains vigilant and responsive to changing global conditions, while strengthening its integrated operations to capture value across the supply chain. In addition, the Group continues to leveraging in technological innovations to enhance yield performance and drive costs efficiencies, and continues commit to sustainability initiatives. These initiatives support the Group's strategy to manage volatility, enhance resilience, and deliver long-term value for stakeholders.

#### 5 Dividend

(a) Current Financial Period Reported On

Any ordinary dividend declared for the current financial period reported on? No

(b) Corresponding Period of the Immediately Preceding Financial Year

Any ordinary dividend declared for the corresponding period of the immediately preceding financial year? No

(c) Date payable

Not applicable

(d) Record date

Not applicable

6 If no dividend has been declared/recommended, a statement to that effect

No dividend has been declared for the half year ended 30 June 2025 as the Company generally reviews its dividend distribution during the second half of the financial year.

## F Other information required by Listing Rule Appendix 7.2 (cont'd)

## 7 Interested persons transactions disclosure

| Name of interested person ("IP")                | Nature of<br>Relationship | Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S\$100,000 and transactions conducted under shareholders' mandate* pursuant to Rule 920) | Aggregate value of all interested person transactions conducted under shareholders' mandate* pursuant to Rule 920 (excluding transactions less than S\$100,000) |
|---|---------------------------|---|---|
|   |                           | USD   | USD   |
| Subsidiaries of Sinarmas Land Limited:          |                           |   |   |
| - PT Bumi Serpong Damai Tbk                     | #1                        | Nil   | 531,299   |
| - PT Duta Cakra Pesona                          | #1                        | Nil   | 1,923,116   |
| - PT Royal Oriental                             | #1                        | Nil   | 4,146,030   |
| Subsidiaries of PT Dian Swastatika Sentosa Tbk: |                           |   |   |
| - PT Rolimex Kimia Nusamas                      | #1                        | Nil   | 14,536,195  |
| - PT Roundhill Capital Indonesia                | #1                        | Nil   | 6,368,621   |
| Subsidiaries of PT Sinar Mas Multiartha Tbk:    |                           |   |   |
| - PT Asuransi Sinar Mas                         | #1                        | Nil   | 7,524,284   |
| - PT Bank Sinarmas Tbk ("BSM")                  | #1                        | Nil   | 8,051,436 #2  |
| - BSM   | #1                        | Nil   | 2,540,000 #3  |
| Total   |                           | Nil   | 45,620,981  |

## Notes:

<sup>\*</sup> Renewed at Annual Meeting on 25 April 2025 pursuant to Rule 920 of the SGX-ST listing manual ("Listing Manual").

<sup>#1</sup> These IPs are regarded as associates of GAR's controlling shareholder under Chapter 9 of the Listing Manual on interested person transactions.

Principal amount of placements, including deposits and bank balances, as at 30 June 2025 is approximately USD4.63 million.

<sup>&</sup>lt;sup>#3</sup> Derivative transactions with BSM.

## F Other information required by Listing Rule Appendix 7.2 (cont'd)

## 8 Confirmation pursuant to the rule 720(1) of the listing manual

The Company confirms that it has procured undertakings from all its directors and executive officers in the form set out in Appendix 7.7 under Rule 720(1) of the Listing Manual.

## 9 Confirmation pursuant to the rule 705(5) of the listing manual

We, Franky Oesman Widjaja and Rafael Buhay Concepcion, Jr., being two directors of Golden Agri-Resources Ltd (the "Company"), do hereby confirm on behalf of the directors of the Company that, to the best of their knowledge, nothing has come to their attention which would render the half year ended 30 June 2025 unaudited financial results to be false or misleading.

On behalf of the board of directors

Franky Oesman Widjaja Director Rafael Buhay Concepcion, Jr. Director

## BY ORDER OF THE BOARD

Rafael Buhay Concepcion, Jr. Director 14 August 2025

Submitted by Pauline Ng, VP, Corporate Secretarial on 14 August 2025 to the SGX